This paper uses patient-derived pancreatic cancer organoids to identify drug sensitivities linked to tumor differentiation and pathway mutations, revealing new therapeutic targets in chemoresistant tumors.

bioRxiv · Dec 3, 2025 · PreprintCancer Biology

Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethality

Chelsea E. Cunningham, Frederick S. Vizeacoumar, Yue Zhang, Liliia Kyrylenko, Simon Both, Vincent Maranda, He Dong, Jared D. W. Price, Peng Gao, Konrad Wagner, Yingwen Wu, Mary Lazell-Wright, Ashtalakshmi Ganapathysamy, Rithik Hari, Kalpana Kalyanasundaram Bhanumathy, , Franco J. Vizeacoumar

The paper identifies synthetic dosage lethality targets for PLK1-overexpressing cancers using genome-wide screens and validates key hits to show their therapeutic potential.

Cell Genomics · May 9, 2025Peer-reviewedCancer Biology

A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate cancer

Prachi Walke, Jared D. W. Price, Frederick S. Vizeacoumar, Nickson Joseph, Vincent Maranda, Bari Chowdhury, Jay Patel, Yue Zhang, He Dong, Lara New, Ashtalakshmi Ganapathysamy, Li Hui Gong, Mary Lazell-Wright, Hussain Elhasasna, Kalpana Kalyanasundaram Bhanumathy, , Franco J. Vizeacoumar

This study identifies Neurog2 as a potential therapeutic target for MYCN-driven neuroendocrine prostate cancer by showing its role in promoting tumor growth and NEPC development.

Oncogene · Apr 29, 2025Peer-reviewedCancer Biology